Jobs
-
3M Drug Delivery Systems will officially open a new 1,300 sq m R&D Inhalation Centre of Excellence on is Charnwood Campus in Loughborough, UK this month, the company said. According to 3M DDS, the new… Read more . . .
-
VistaGen Therapeutics has presented new data from a Phase 3 study of PH94B nasal spray for the treatment of social anxiety disorder (SAD) at the 2019 Anxiety and Depression Association of America (ADAA) Annual Conference.… Read more . . .
-
Savara has announced the initiation of the Phase 2a ENCORE study of its Molgradex inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of nontuberculous mycobacterial (NTM) lung infection in cystic fibrosis patients. The… Read more . . .
-
The FDA has approved Duaklir Pressair aclidinium bromide/formoterol fumarate DPI for the treatment of COPD, Circassia Pharmaceuticals has announced. Circassia said in August 2018 that the FDA had accepted the NDA for Duaklir and an… Read more . . .
-
Biohaven Pharmaceutical said that it has initiated a Phase 2/3 study of its BHV-3500 intranasal calcitonin gene-related peptide (CGRP) receptor antagonist for the treatment of migraine. The company announced positive results from a Phase 1… Read more . . .
-
According to Circassia Pharmaceuticals, the FDA has approved the company’s sNDA for the addition of data from the Phase 4 ASCENT study of the Tudorza Pressair aclidinium bromide DPI in COPD patients showing significant reduction… Read more . . .
-
The Alzheimer’s Drug Discovery Foundation has awarded a grant worth approximately $1.2 million to a team led by Hiroaki Sato and Thomas Schricker at the Research Institute of the McGill University Health Centre (RI-MUHC) for… Read more . . .
-
Auris Medical has announced the initiation of a Phase 1b proof-of-concept study of its AM-201 intranasal betahistine, which the company is developing for the prevention of weight gain and sleepiness in patients taking olanzapine. The… Read more . . .
-
Mundipharma initiates Phase 3 trial of Penthrox in trauma patients rescued from hostile environments
Mundipharma has announced enrollment of the first patient in the Phase 3b METEORA trial of Penthrox inhaled methoxyflurane in patients with limb trauma who have been rescued by helicopter from hostile terrain and are suffering… Read more . . .
-
Synspira Therapeutics, which is developing an inhaled therapy for cystic fibrosis, has announced the appointment of Robert Gallotto as President and CEO. Gallotto was most recently President and co-founder of Alcresta Therapeutics. He previously co-founded… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 9-June 10: Nasal Drug Delivery Symposium: Current Status and Future Opportunities, Stockholm, Sweden
June 10: SMI.London 2026, London, UK